527 results on '"KAVAKLI, Kaan"'
Search Results
2. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
3. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
4. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial
5. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
6. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
7. Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
8. Accuracy and clinical role of digital templating for total knee arthroplasty performed on haemophilic knees.
9. Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single‐arm, open‐label study
10. Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency
11. Plasma‐derived factor X concentrate compassionate use for hereditary factor X deficiency: Long‐term safety and efficacy in a retrospective data‐collection study
12. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients
13. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial
14. Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency
15. A unique case of thrombophilia: the role of F9 gene duplication and increased factor IX activity in cerebral venous thrombosis
16. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results
17. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies
18. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
19. Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency.
20. S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS
21. HTRS2023.P2.9 Fitusiran prophylaxis demonstrates sustained bleed protection in people with hemophilia A or B: an exploratory analysis of antithrombin levels and peak thrombin generation from three phase 3 trials
22. S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
23. Evaluation of Bleeding Phenotype of Inherited Factor VII Deficiency in Children With a Bleeding Assessment Tool and Global Assays
24. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
25. Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency
26. A unique case of thrombophilia: the role of F9gene duplication and increased factor IX activity in cerebral venous thrombosis
27. Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
28. Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study
29. Management of haemophilia A with inhibitors: A regional cross‐talk
30. Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial
31. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B – the impact of prophylactic treatment
32. Are all licensed haemostatic agents for haemophilia therapy accessible to patients?
33. Fitusiran prophylaxis improves health-related quality of life in people with haemophilia A or B without inhibitors: Results of phase 3 ATLAS-A/B randomized control trial
34. Management of haemophilia A with inhibitors: A regional cross-talk
35. Gene therapy in haemophilia: literature review and regional perspectives for Turkey
36. Molecular spectrum of Von Willebrand Disease Type 3
37. Hematuria in Patients with Congenital Coagulation Factor Deficiencies
38. Efficacy and safety of a VWF/FVIII concentrate (wilate®) in inherited von Willebrand disease patients undergoing surgical procedures
39. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial
40. The value of ultrasonography in detecting early arthropathic changes and contribution to the clinical approach in patients of hemophilia
41. Effect of CTLA-4 and TNF-α Gene Polymorphisms on Inhibitor Development in a Turkish Cohort of Severe Hemophilia A Cases with Intron 22 Inversion Mutation: An Analytical Study
42. Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)
43. Recombinant Porcine Factor VIII in Patients with Congenital Hemophilia a with Inhibitors Undergoing Surgery: Phase 3, Multicenter, Single Arm, Open-Label Study
44. Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials
45. Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)
46. Hemofilide Yeni Tedavi Seçeneklerinde Hasta ve Hasta Yakını Perspektifi
47. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
48. FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies
49. Prophylaxis in children with haemophilia in an evolving treatment landscape
50. Proven and probable invasive fungal infections in children with acute lymphoblastic leukaemia: results from an university hospital, 2005–2013
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.